Ceribell Inc

Chao Xingjuan’s 14,000‑share sale via a 10(b)(5)(1) plan shows Ceribell’s CEO balancing liquidity and confidence, yet not harming the stock’s steady rise.

Insider trading at Ceribell Inc. reveals how CTO Woo Raymond’s large 10‑b5‑1 trades may signal confidence, influence R&D funding, and impact the company’s AI‑driven EEG market.

Insider trading at Ceribell: Finance chief David Foehr’s February 2026 sales show routine tax‑liquidity moves, not market‑timing, keeping the company’s bullish 2026 outlook intact.

Insider sales at Ceribell highlight a balanced liquidity strategy while the AI‑powered EEG platform shows strong clinical accuracy, safety, and expanding regulatory approvals.

Insightful analysis of Ceribell’s insider trades, clinical data and FDA roadmap reveals whether the neurofeedback tech can spark a stock rally or stay flat.

CEO trades signal routine rebalancing, not a warning for Ceribell. Discover how new EEG evidence, FDA guidance and AI upgrades could shape its future.

Discover how Ceribell’s insider trades, clinical data, and regulatory milestones point to future growth—and what that means for investors and neurologists.

CTO’s rule‑based buy at $2.24 shows confidence in Ceribell’s rapid, wireless EEG system—yet investors weigh its high volatility, negative earnings and payer‑reimbursement risks.